Degradable polyprodrugs: design and therapeutic efficiency

F Seidi, Y Zhong, H **ao, Y **, D Crespy - Chemical Society Reviews, 2022 - pubs.rsc.org
Prodrugs are developed to increase the therapeutic properties of drugs and reduce their
side effects. Polyprodrugs emerged as highly efficient prodrugs produced by the …

Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer

A Leonetti, B Wever, G Mazzaschi, YG Assaraf… - Drug Resistance …, 2019 - Elsevier
Immunotherapy has prompted a paradigm shift in advanced non-small cell lung cancer
(NSCLC) treatment, by demonstrating superior efficacy to chemotherapy alone both in …

High‐Load Gemcitabine Inorganic–Organic Hybrid Nanoparticles as an Image‐Guided Tumor‐Selective Drug‐Delivery System to Treat Pancreatic Cancer

M Ischyropoulou, K Sabljo, L Schneider… - Advanced …, 2023 - Wiley Online Library
Pancreatic ductal adenocarcinoma (PDAC) has a devastating prognosis without effective
treatment options. Thus, there is an urgent need for more effective and safe therapies. Here …

Deoxycytidine release from pancreatic stellate cells promotes gemcitabine resistance

S Dalin, MR Sullivan, AN Lau, B Grauman-Boss… - Cancer research, 2019 - AACR
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer deaths in the
United States. The deoxynucleoside analogue gemcitabine is among the most effective …

[HTML][HTML] Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance

M Capula, M Perán, G Xu, V Donati, D Yee… - Drug Resistance …, 2022 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) has one of the highest incidence/death ratios
among all neoplasms due to its late diagnosis and dominant chemoresistance. Most PDAC …

Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer

M Le Compte, EC De La Hoz, S Peeters… - NPJ Precision …, 2023 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, characterized
by a treatment-resistant and invasive nature. In line with these inherent aggressive …

Comprehensive molecular characterization identifies distinct genomic and immune hallmarks of renal medullary carcinoma

P Msaouel, GG Malouf, X Su, H Yao, DN Tripathi… - Cancer Cell, 2020 - cell.com
Renal medullary carcinoma (RMC) is a highly lethal malignancy that mainly afflicts young
individuals of African descent and is resistant to all targeted agents used to treat other renal …

Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer

G Iyer, AV Balar, MI Milowsky, BH Bochner… - Journal of clinical …, 2018 - ascopubs.org
Purpose Neoadjuvant chemotherapy followed by radical cystectomy (RC) is a standard of
care for the management of muscle-invasive bladder cancer (MIBC). Dose-dense cisplatin …

Cell counting and viability assessment of 2D and 3D cell cultures: expected reliability of the trypan blue assay

F Piccinini, A Tesei, C Arienti, A Bevilacqua - Biological procedures online, 2017 - Springer
Background Whatever the target of an experiment in cell biology, cell counting and viability
assessment are always computed. The Trypan Blue (TB) assay was proposed about a …

[HTML][HTML] Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape

KA Olaussen, S Postel-Vinay - Annals of Oncology, 2016 - Elsevier
Background Conventional cytotoxic chemotherapy (CCC) is the backbone of non-small-cell
lung cancer (NSCLC) treatment since decades and still represents a key element of the …